Skip to main content
Erschienen in: The European Journal of Health Economics 5/2019

06.03.2019 | Original Paper

A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer

verfasst von: Cuc Thi Thu Nguyen, Fabio Petrelli, Stefania Scuri, Binh Thanh Nguyen, Iolanda Grappasonni

Erschienen in: The European Journal of Health Economics | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

To review and assess the quality of the available evidence on the cost-effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer (NSCLC).

Methods

A systematic review was conducted to identify full-text original economic evaluations of erlotinib in the first-line treatment of advanced NSCLC written in English and published from the year 2000 onwards. Study characteristics and results were recorded and compared. The quality of the studies was assessed by the Quality of Health Economic Studies (QHES) questionnaire.

Results

Eleven out of 130 papers were chosen for this review. Comparative regimens consisted of a best supportive care, reverse strategy, bevacizumab, cisplatin plus pemetrexed, carboplatin plus gemcitabine or gefitinib. The methods most used in these studies were modeling and sensitivity analysis and cost-effectiveness analysis. All of the studies evaluated direct costs and used quality-adjusted life-year (QALY) and life-years gained (LYG) as outcome, with 3% and 3.5% discount rate. The studies assigned ICER that ranged from dominant to I$305,510.31/QALY and from I$31,209.55/LYG to I$66,540.20/LYG. Based on the willingness to pay threshold, seven studies concluded that erlotinib was cost-effective, two studies showed that erlotinib was cost-effective on specific patients with certain conditions, and two studies comparing erlotinib with reverse strategy did not find a difference in cost-effectiveness. The high quality of these studies was confirmed using the QHES tool: the mean score was 75.77 out of 100 (SD 9.38).

Conclusion

Most of these high-quality studies suggested that erlotinib was cost-effective in the first-line treatment of advanced NSCLC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
7.
Zurück zum Zitat Grappasonni, I., Marconi, D., Mazzucchi, F., Petrelli, F., Scuri, S., Amenta, F.: Survey on food hygiene knowledge on board ships. Int Marit Health 64(3), 160–167 (2013)PubMed Grappasonni, I., Marconi, D., Mazzucchi, F., Petrelli, F., Scuri, S., Amenta, F.: Survey on food hygiene knowledge on board ships. Int Marit Health 64(3), 160–167 (2013)PubMed
8.
Zurück zum Zitat Grappasonni, I., Petrelli, F., Klusoňová, H., Kračmarová, L.: Level of understanding of medical terms among italian students. Ceska Slov Farm. Winter 65(6), 216–220 (2016) Grappasonni, I., Petrelli, F., Klusoňová, H., Kračmarová, L.: Level of understanding of medical terms among italian students. Ceska Slov Farm. Winter 65(6), 216–220 (2016)
9.
Zurück zum Zitat Spacilova, L., Klusonova, H., Petrelli, F., Signorelli, C., Visnovsky, P., Grappasonni, I.: Substance use and knowledge among Italian high school students. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 153(2), 163–168 (2009)CrossRefPubMed Spacilova, L., Klusonova, H., Petrelli, F., Signorelli, C., Visnovsky, P., Grappasonni, I.: Substance use and knowledge among Italian high school students. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 153(2), 163–168 (2009)CrossRefPubMed
10.
Zurück zum Zitat Kračmarová, L., Klusoňová, H., Petrelli, F., Grappasonni, I.: Tobacco, alcohol and illegal substances: experiences and attitudes among Italian university students. Rev. Assoc. Med. Bras. (1992) 57(5), 523–528 (2011)CrossRef Kračmarová, L., Klusoňová, H., Petrelli, F., Grappasonni, I.: Tobacco, alcohol and illegal substances: experiences and attitudes among Italian university students. Rev. Assoc. Med. Bras. (1992) 57(5), 523–528 (2011)CrossRef
13.
Zurück zum Zitat Ferlay, J.S.-F., Lortet-Tieulent, E., Rosso, J., Coebergh, S., Jan-Willem, W., Comber, H., Forman, D., Bray, F.: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6), 1374–1403 (2013)CrossRef Ferlay, J.S.-F., Lortet-Tieulent, E., Rosso, J., Coebergh, S., Jan-Willem, W., Comber, H., Forman, D., Bray, F.: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6), 1374–1403 (2013)CrossRef
15.
Zurück zum Zitat Siegel, R., Naishadham, D., Jemal, A.: Cancer statistics, 2013. CA Cancer J. Clin. 63(1), 11–30 (2013)CrossRefPubMed Siegel, R., Naishadham, D., Jemal, A.: Cancer statistics, 2013. CA Cancer J. Clin. 63(1), 11–30 (2013)CrossRefPubMed
16.
Zurück zum Zitat Navada, S., Lai, P., Schwartz, A., Kalemkerian, G.: Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database. J. Clin. Oncol. 24(18_suppl), 7082–7082 (2006) Navada, S., Lai, P., Schwartz, A., Kalemkerian, G.: Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database. J. Clin. Oncol. 24(18_suppl), 7082–7082 (2006)
17.
Zurück zum Zitat Sher, T., Dy, G.K., Adjei, A.A.: Small cell lung cancer. In: Mayo Clinic Proceedings 2008, vol. 3, pp. 355–367. Elsevier Sher, T., Dy, G.K., Adjei, A.A.: Small cell lung cancer. In: Mayo Clinic Proceedings 2008, vol. 3, pp. 355–367. Elsevier
19.
Zurück zum Zitat Spiro, S.G., Gould, M.K., Colice, G.L.: Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edn.). Chest 132(3 Suppl), 149 s–160 s (2007). https://doi.org/10.1378/chest.07-1358 CrossRef Spiro, S.G., Gould, M.K., Colice, G.L.: Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edn.). Chest 132(3 Suppl), 149 s–160 s (2007). https://​doi.​org/​10.​1378/​chest.​07-1358 CrossRef
20.
Zurück zum Zitat Cuccioloni, M., Bonfili, L., Mozzicafreddo, M., Cecarini, V., Scuri, S., Cocchioni, M., Nabissi, M., Santoni, G., Eleuteri, A.M., Angeletti, M.: Mangiferin blocks proliferation and induces apoptosis of breast cancer cells via suppression of the mevalonate pathway and by proteasome inhibition. Food Funct. 7(10), 4299–4309 (2016)CrossRefPubMed Cuccioloni, M., Bonfili, L., Mozzicafreddo, M., Cecarini, V., Scuri, S., Cocchioni, M., Nabissi, M., Santoni, G., Eleuteri, A.M., Angeletti, M.: Mangiferin blocks proliferation and induces apoptosis of breast cancer cells via suppression of the mevalonate pathway and by proteasome inhibition. Food Funct. 7(10), 4299–4309 (2016)CrossRefPubMed
22.
Zurück zum Zitat Marchetti, A., Martella, C., Felicioni, L., Barassi, F., Salvatore, S., Chella, A., Camplese, P.P., Iarussi, T., Mucilli, F., Mezzetti, A., Cuccurullo, F., Sacco, R., Buttitta, F.: EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. 23(4), 857–865 (2005). https://doi.org/10.1200/jco.2005.08.043 CrossRefPubMed Marchetti, A., Martella, C., Felicioni, L., Barassi, F., Salvatore, S., Chella, A., Camplese, P.P., Iarussi, T., Mucilli, F., Mezzetti, A., Cuccurullo, F., Sacco, R., Buttitta, F.: EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. 23(4), 857–865 (2005). https://​doi.​org/​10.​1200/​jco.​2005.​08.​043 CrossRefPubMed
23.
Zurück zum Zitat Doval, D., Prabhash, K., Patil, S., Chaturvedi, H., Goswami, C., Vaid, A., Desai, S., Dutt, S., Veldore, V., Jambhekar, N., Mehta, A., Hazarika, D., Azam, S., Gawande, S., Gupta, S.: Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. Oncotargets Ther. 8, 117–123 (2015). https://doi.org/10.2147/ott.s74820 CrossRef Doval, D., Prabhash, K., Patil, S., Chaturvedi, H., Goswami, C., Vaid, A., Desai, S., Dutt, S., Veldore, V., Jambhekar, N., Mehta, A., Hazarika, D., Azam, S., Gawande, S., Gupta, S.: Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. Oncotargets Ther. 8, 117–123 (2015). https://​doi.​org/​10.​2147/​ott.​s74820 CrossRef
25.
Zurück zum Zitat Cioffi, P., Marotta, V., Fanizza, C., Giglioni, A., Natoli, C., Petrelli, F., Grappasonni, I.: Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study. J. Oncol. Pharm. Pract. 19(3), 246–253 (2013). https://doi.org/10.1177/1078155212465994 CrossRefPubMed Cioffi, P., Marotta, V., Fanizza, C., Giglioni, A., Natoli, C., Petrelli, F., Grappasonni, I.: Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study. J. Oncol. Pharm. Pract. 19(3), 246–253 (2013). https://​doi.​org/​10.​1177/​1078155212465994​ CrossRefPubMed
26.
Zurück zum Zitat De Grève, J., Van Meerbeeck, J., Vansteenkiste, J.F., Decoster, L., Meert, A.P., Vuylsteke, P., Focan, C., Canon, J.L., Humblet, Y., Berchem, G., Colinet, B., Galdermans, D., Bosquée, L., Vermeij, J., Dewaele, A., Geers, C., Schallier, D., Teugels, E.: Prospective evaluation of first-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating egfr mutation: a multicenter academic phase II study in caucasian patients (FIELT). PLoS One (2016). https://doi.org/10.1371/journal.pone.0147599 CrossRefPubMedPubMedCentral De Grève, J., Van Meerbeeck, J., Vansteenkiste, J.F., Decoster, L., Meert, A.P., Vuylsteke, P., Focan, C., Canon, J.L., Humblet, Y., Berchem, G., Colinet, B., Galdermans, D., Bosquée, L., Vermeij, J., Dewaele, A., Geers, C., Schallier, D., Teugels, E.: Prospective evaluation of first-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating egfr mutation: a multicenter academic phase II study in caucasian patients (FIELT). PLoS One (2016). https://​doi.​org/​10.​1371/​journal.​pone.​0147599 CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Zhou, C., Wu, Y.L., Chen, G., Feng, J., Liu, X.Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., Lu, S., Zhang, L., Hu, C., Hu, C., Luo, Y., Chen, L., Ye, M., Huang, J., Zhi, X., Zhang, Y., Xiu, Q., Ma, J., Zhang, L., You, C.: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12(8), 735–742 (2011). https://doi.org/10.1016/s1470-2045(11)70184-x CrossRefPubMed Zhou, C., Wu, Y.L., Chen, G., Feng, J., Liu, X.Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., Lu, S., Zhang, L., Hu, C., Hu, C., Luo, Y., Chen, L., Ye, M., Huang, J., Zhi, X., Zhang, Y., Xiu, Q., Ma, J., Zhang, L., You, C.: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12(8), 735–742 (2011). https://​doi.​org/​10.​1016/​s1470-2045(11)70184-x CrossRefPubMed
28.
Zurück zum Zitat Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J.M., Porta, R., Cobo, M., Garrido, P., Longo, F., Moran, T., Insa, A., De Marinis, F., Corre, R., Bover, I., Illiano, A., Dansin, E., de Castro, J., Milella, M., Reguart, N., Altavilla, G., Jimenez, U., Provencio, M., Moreno, M.A., Terrasa, J., Munoz-Langa, J., Valdivia, J., Isla, D., Domine, M., Molinier, O., Mazieres, J., Baize, N., Garcia-Campelo, R., Robinet, G., Rodriguez-Abreu, D., Lopez-Vivanco, G., Gebbia, V., Ferrera-Delgado, L., Bombaron, P., Bernabe, R., Bearz, A., Artal, A., Cortesi, E., Rolfo, C., Sanchez-Ronco, M., Drozdowskyj, A., Queralt, C., de Aguirre, I., Ramirez, J.L., Sanchez, J.J., Molina, M.A., Taron, M., Paz-Ares, L.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13(3), 239–246 (2012). https://doi.org/10.1016/s1470-2045(11)70393-x CrossRefPubMed Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J.M., Porta, R., Cobo, M., Garrido, P., Longo, F., Moran, T., Insa, A., De Marinis, F., Corre, R., Bover, I., Illiano, A., Dansin, E., de Castro, J., Milella, M., Reguart, N., Altavilla, G., Jimenez, U., Provencio, M., Moreno, M.A., Terrasa, J., Munoz-Langa, J., Valdivia, J., Isla, D., Domine, M., Molinier, O., Mazieres, J., Baize, N., Garcia-Campelo, R., Robinet, G., Rodriguez-Abreu, D., Lopez-Vivanco, G., Gebbia, V., Ferrera-Delgado, L., Bombaron, P., Bernabe, R., Bearz, A., Artal, A., Cortesi, E., Rolfo, C., Sanchez-Ronco, M., Drozdowskyj, A., Queralt, C., de Aguirre, I., Ramirez, J.L., Sanchez, J.J., Molina, M.A., Taron, M., Paz-Ares, L.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13(3), 239–246 (2012). https://​doi.​org/​10.​1016/​s1470-2045(11)70393-x CrossRefPubMed
32.
Zurück zum Zitat Vergnenegre, A., Massuti, B., de Marinis, F., Carcereny, E., Felip, E., Do, P., Sanchez, J.M., Paz-Arez, L., Chouaid, C., Rosell, R.: Economic analysis of first-line treatment with erlotinib in an EGFR-mutated population with advanced NSCLC. J. Thorac. Oncol. 11(6), 801–807 (2016)CrossRefPubMed Vergnenegre, A., Massuti, B., de Marinis, F., Carcereny, E., Felip, E., Do, P., Sanchez, J.M., Paz-Arez, L., Chouaid, C., Rosell, R.: Economic analysis of first-line treatment with erlotinib in an EGFR-mutated population with advanced NSCLC. J. Thorac. Oncol. 11(6), 801–807 (2016)CrossRefPubMed
33.
Zurück zum Zitat Khan, I., Morris, S., Hackshaw, A., Lee, S.-M.: Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy. BMJ Open 5(7), e006733 (2015)CrossRefPubMedPubMedCentral Khan, I., Morris, S., Hackshaw, A., Lee, S.-M.: Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy. BMJ Open 5(7), e006733 (2015)CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Schremser, K., Rogowski, W.H., Adler-Reichel, S., Tufman, A.L., Huber, R.M., Stollenwerk, B.: Cost-effectiveness of an individualized first-line treatment strategy offering erlotinib based on EGFR mutation testing in advanced lung adenocarcinoma patients in Germany. Pharmacoeconomics 33(11), 1215–1228 (2015)CrossRefPubMed Schremser, K., Rogowski, W.H., Adler-Reichel, S., Tufman, A.L., Huber, R.M., Stollenwerk, B.: Cost-effectiveness of an individualized first-line treatment strategy offering erlotinib based on EGFR mutation testing in advanced lung adenocarcinoma patients in Germany. Pharmacoeconomics 33(11), 1215–1228 (2015)CrossRefPubMed
36.
Zurück zum Zitat Chouaid, C., Le Caer, H., Corre, R., Crequit, J., Locher, C., Falchero, L., Dujon, C., Berard, H., Monnet, I., Vergnenegre, A.: Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505). Clin. Lung Cancer 14(2), 103–107 (2013)CrossRefPubMed Chouaid, C., Le Caer, H., Corre, R., Crequit, J., Locher, C., Falchero, L., Dujon, C., Berard, H., Monnet, I., Vergnenegre, A.: Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505). Clin. Lung Cancer 14(2), 103–107 (2013)CrossRefPubMed
37.
Zurück zum Zitat Vergnenègre, A., Ray, J.A., Chouaid, C., Grossi, F., Bischoff, H.G., Heigener, D.F., Walzer, S.: Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer. Clinicoecon. Outcomes Res. CEOR 4, 31 (2012)CrossRef Vergnenègre, A., Ray, J.A., Chouaid, C., Grossi, F., Bischoff, H.G., Heigener, D.F., Walzer, S.: Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer. Clinicoecon. Outcomes Res. CEOR 4, 31 (2012)CrossRef
38.
Zurück zum Zitat Walleser, S., Ray, J., Bischoff, H., Vergnenègre, A., Rosery, H., Chouaid, C., Heigener, D., de Castro Carpeño, J., Tiseo, M., Walzer, S.: Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe. Clinicoecon. Outcomes Res. CEOR 4, 269 (2012) Walleser, S., Ray, J., Bischoff, H., Vergnenègre, A., Rosery, H., Chouaid, C., Heigener, D., de Castro Carpeño, J., Tiseo, M., Walzer, S.: Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe. Clinicoecon. Outcomes Res. CEOR 4, 269 (2012)
39.
Zurück zum Zitat Lee, V.W., Schwander, B., Lee, V.H.: Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong. Hong Kong Med. J. 20(3), 178–186 (2014)CrossRefPubMed Lee, V.W., Schwander, B., Lee, V.H.: Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong. Hong Kong Med. J. 20(3), 178–186 (2014)CrossRefPubMed
40.
Zurück zum Zitat Wang, S., Peng, L., Li, J., Zeng, X., Ouyang, L., Tan, C., Lu, Q.: A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer. PLoS One 8(3), e55917 (2013)CrossRefPubMedPubMedCentral Wang, S., Peng, L., Li, J., Zeng, X., Ouyang, L., Tan, C., Lu, Q.: A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer. PLoS One 8(3), e55917 (2013)CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Lv, F., Yu, K., Gao, W., Yu, S.: Cost-utility of erlotinib combined with bevacizumab versus bevacizumab alone after completion of chemotherapy with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J. Chin. Pharm. Sci. 26(6), 447–454 (2017) Lv, F., Yu, K., Gao, W., Yu, S.: Cost-utility of erlotinib combined with bevacizumab versus bevacizumab alone after completion of chemotherapy with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J. Chin. Pharm. Sci. 26(6), 447–454 (2017)
42.
Zurück zum Zitat Ting, J., Ho, P.T., Xiang, P., Sugay, A., Abdel-Sattar, M., Wilson, L.: Cost-effectiveness and value of information of erlotinib, afatinib, and cisplatin-pemetrexed for first-line treatment of advanced EGFR mutation-positive non-small-cell lung cancer in the United States. Value Health 18(6), 774–782 (2015)CrossRefPubMed Ting, J., Ho, P.T., Xiang, P., Sugay, A., Abdel-Sattar, M., Wilson, L.: Cost-effectiveness and value of information of erlotinib, afatinib, and cisplatin-pemetrexed for first-line treatment of advanced EGFR mutation-positive non-small-cell lung cancer in the United States. Value Health 18(6), 774–782 (2015)CrossRefPubMed
43.
Zurück zum Zitat Christos, C., Chrystelle, L., Cecile, D., Pascal, T., Bernard, A.J., Isabelle, M., Alain, V.: Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504). BMC Cancer 12(1), 301 (2012)CrossRefPubMedCentral Christos, C., Chrystelle, L., Cecile, D., Pascal, T., Bernard, A.J., Isabelle, M., Alain, V.: Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504). BMC Cancer 12(1), 301 (2012)CrossRefPubMedCentral
44.
Zurück zum Zitat Marshall, D.A., Donald, F., Lacny, S., Reid, K., Bryant-Lukosius, D., Carter, N., Charbonneau-Smith, R., Harbman, P., Kaasalainen, S., Kilpatrick, K.: Assessing the quality of economic evaluations of clinical nurse specialists and nurse practitioners: a systematic review of cost-effectiveness. NursingPlus Open 1, 11–17 (2015)CrossRef Marshall, D.A., Donald, F., Lacny, S., Reid, K., Bryant-Lukosius, D., Carter, N., Charbonneau-Smith, R., Harbman, P., Kaasalainen, S., Kilpatrick, K.: Assessing the quality of economic evaluations of clinical nurse specialists and nurse practitioners: a systematic review of cost-effectiveness. NursingPlus Open 1, 11–17 (2015)CrossRef
45.
Zurück zum Zitat Jäkel, A., Plested, M., Dharamshi, K., Modha, R., Bridge, S., Johns, A.: A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer. Appl. Health Econ. Health Policy 11(1), 27–43 (2013)CrossRefPubMed Jäkel, A., Plested, M., Dharamshi, K., Modha, R., Bridge, S., Johns, A.: A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer. Appl. Health Econ. Health Policy 11(1), 27–43 (2013)CrossRefPubMed
46.
Zurück zum Zitat Lange, A., Prenzler, A., Frank, M., Golpon, H., Welte, T., von der Schulenburg, J.-M.: A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC). BMC Pulm. Med. 14(1), 192 (2014)CrossRefPubMedPubMedCentral Lange, A., Prenzler, A., Frank, M., Golpon, H., Welte, T., von der Schulenburg, J.-M.: A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC). BMC Pulm. Med. 14(1), 192 (2014)CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Siebert, U.: When Should Decision-Analytic Modeling be Used in the Economic Evaluation of Health Care? Springer, Berlin (2003)CrossRef Siebert, U.: When Should Decision-Analytic Modeling be Used in the Economic Evaluation of Health Care? Springer, Berlin (2003)CrossRef
53.
Zurück zum Zitat Desai, P.R., Chandwani, H.S., Rascati, K.L.: Assessing the quality of pharmacoeconomic studies in India. Pharmacoeconomics 30(9), 749–762 (2012)CrossRefPubMed Desai, P.R., Chandwani, H.S., Rascati, K.L.: Assessing the quality of pharmacoeconomic studies in India. Pharmacoeconomics 30(9), 749–762 (2012)CrossRefPubMed
Metadaten
Titel
A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
verfasst von
Cuc Thi Thu Nguyen
Fabio Petrelli
Stefania Scuri
Binh Thanh Nguyen
Iolanda Grappasonni
Publikationsdatum
06.03.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
The European Journal of Health Economics / Ausgabe 5/2019
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-019-01040-7

Weitere Artikel der Ausgabe 5/2019

The European Journal of Health Economics 5/2019 Zur Ausgabe